Tags : MR

Abbott’s MitraClip Device Receives FDA’s Expanded Indication Approval for Secondary

Vartika Singh March 15, 2019

Shots: The approval is based on COAPT study assessing MitraClip + medical therapy vs medical therapy as monothx. in 614 patients with moderate to severe secondary MR across 78sites including […]readmore

Tags : MR

Abbott’s MitraClip Device Receives FDA’s Expanded Indication Approval for Secondary

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : MR

﻿Abbott’s MitraClip Device Receives FDA’s Expanded Indication Approval for Secondary

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Abbott’s MitraClip Device Receives FDA’s Expanded Indication Approval for Secondary